Stock comparison
AnaptysBio
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ANAB
AnaptysBio
Market cap
$2.57B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ANAB | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 29F | 79B | HALO |
| Benjamin Graham | 66D | 83A | HALO |
| Philip Fisher | 43D | 65B | HALO |
| Peter Lynch | 77B | 53D | ANAB |
| Joel Greenblatt | 54C | 40D | ANAB |
| Charlie Munger | 35D | 80C | HALO |
| Terry Smith | 30F | 84A | HALO |
Side-by-side metrics
| Metric | ANAB | HALO |
|---|---|---|
| Market cap | $2.57B | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | 55.0x | 10.2x |
| ROIC (TTM) | 14.06% | 23.65% |
| Gross margin | 116.42% | 81.24% |
| Net margin | -11.53% | 23.13% |
| Revenue CAGR 5y | 38.82% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 21.8x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ANAB leads on
- P/E (TTM)-vs 24.0x+137%
- Gross margin116.42%vs 81.24%+30%
- Revenue CAGR 5y38.82%vs 33.23%+14%
HALO leads on
- Net margin23.13%vs -11.53%+150%
- Debt / Equity1.0xvs 21.8x+96%
- EV/EBIT10.2xvs 55.0x+81%
- Market cap$8.1Bvs $2.57B+68%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.